APONTIS PHARMA Boosts Forecast After 5-Year Deal with Novartis for Asthma Drugs

• APONTIS PHARMA AG has entered a five-year distribution and marketing agreement with Novartis Pharma GmbH for two asthma medications in Germany.
• The company expects a sales contribution of around EUR 9 million and an earnings contribution of up to EUR 1.5 million for the 2024 financial year from this agreement.
• APONTIS PHARMA is raising its forecast for 2024 due to this agreement.
• The company now expects an increase in sales to EUR 50.7 million, up from the previous forecast of EUR 41.7 million.
• APONTIS PHARMA also expects a positive EBITDA of EUR 3.3 million, up from the previous forecast of a positive EBITDA of EUR 1.8 million.
• The announcement was made on 5 April 2024.

The price of APONTIS PHARMA at the time of the news was 7,0400EUR and was up +0,72 % compared with the previous day.
15 minutes after the article was published, the price was 8,0000EUR this corresponds to a plus of +13,64 % since publication.

APONTIS PHARMA

-0,85 %

+3,14 %

+28,53 %

+87,00 %

-27,75 %

-56,27 %

ISIN:DE000A3CMGM5WKN:A3CMGM

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• Max